BiotechTube

LAG525 + PDR001 + Carboplatin

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple-negative Breast Cancer

Conditions

Triple-negative Breast Cancer

Trial Timeline

Jul 2, 2018 → Nov 24, 2021

NCT ID
NCT03499899

About LAG525 + PDR001 + Carboplatin

LAG525 + PDR001 + Carboplatin is a phase 2 stage product being developed by Novartis for Triple-negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03499899. Target conditions include Triple-negative Breast Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03499899Phase 2Completed

Competing Products

20 competing products in Triple-negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Cisplatin + AZD1775AstraZenecaPhase 2
52
olaparib + DurvalumabAstraZenecaPhase 2
52
AZD2014 + AZD6244AstraZenecaPhase 1/2
41
OlaparibAstraZenecaPhase 1
33
Carboplatin + Docetaxel + Pembrolizumab + PegfilgrastimMerckPhase 2
52
Pembrolizumab + Sacituzumab tirumotecan + CapecitabineMerckPhase 3
77
AN0025 + PembrolizumabMerckPhase 1
33
Pembrolizumab + AxatilimabMerckPhase 2
52
AE37 Peptide vaccine + PembrolizumabMerckPhase 2
52
Pembrolizumab + AxatilimabMerckPhase 2
52
Zilovertamab vedotinMerckPhase 2
52
Pembrolizumab + Paclitaxel + BevacizumabMerckPhase 2
52
OlinvacimabMerckPhase 2
52
Trilaciclib + Pembrolizumab + Gemcitabine + CarboplatinMerckPhase 2
52
Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for IpatasertibRochePhase 3
77
Atezolizumab + Nab-PaclitaxelRochePhase 3
77
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Atezolizumab Placebo + PaclitaxelRochePhase 3
77
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Placebo + Nab-paclitaxel + Doxorubicin + Cyclophosphamide + Filgrastim + PegfilgrastimRochePhase 3
77
Tiragolumab + Atezolizumab + Nab-paclitaxel + Tiragolumab + Atezolizumab + Nab-paclitaxel + Carboplatin + Doxorubicin + Cyclophosphamide + Granulocyte colony-stimulating factor (G-CSF) + Granulocyte-macrophage colony-stimulating factor (GM-CSF)RochePhase 1
33

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85